GREENCORE GROUP PLC (GNC) — Investment Research Note

Executive summary

Greencore is the UK's leading fresh convenience-food manufacturer (sandwiches, salads, sushi, ready meals, pizza, quiche, sauces) supplying every major UK grocer, dramatically re-scaled by the £1.5bn all-share/cash acquisition of Bakkavor in January 2026, creating a c.£4bn revenue combined UK champion. Operating trajectory across the period is a textbook self-help recovery — post-COVID margin rebuild, disciplined portfolio pruning (H1 25 ROIC 13.1%, FY25 15.0%), then the transformative M&A step-up with £80m annualised cost synergies underwriting FY26–FY29 earnings growth. The single most important valuation point today is that management has now twice upgraded FY26 Adjusted Operating Profit guidance for the enlarged group to £234–242m (17–21% pro-forma growth) with c.£15m in-year synergy delivery, meaning the shares are already discounting solid execution 2026-07-22 Q3 trading update.

Fair value estimate

• Fair value range: 230p – 290p per share (mid ~260p), implying market cap of £1,825m – £2,300m, mid ~£2,062m.
• Methodology: Blend of (i) forward EV/EBITDA on FY27E and (ii) forward P/E on adjusted EPS.
  • Building blocks: FY26 AOP £238m (midpoint) + underlying growth 3–5% + step-up in synergy run-rate to 85% by Jan 2028 (£68m annualised vs ~£40m by Jan 2027) → FY27E AOP ~£275–290m; add ~£100m D&A → FY27E EBITDA ~£380m.
  • EV/EBITDA 7–8x (UK food manufacturers historically 7–9x; Bakkavor was acquired at c.7.9x) → EV £2.66–3.04bn; less pro-forma net debt ~£700m post likely US divestiture → equity £1.96–2.34bn → 247p–295p.
  • P/E cross-check: FY27E adjusted EPS ~19–21p at 12–14x → 228p–294p.
• Vs current £2,116m market cap: absolute upside ~-1.8% at midpoint — shares roughly fair.

Sector context

• ICB classification confirmed: Consumer Staples / Food, Beverage & Tobacco — appropriate.
• Quality/growth is in line with UK food manufacturing peers, with above-peer growth momentum from synergies but below-peer margins (5.6% H1 26 AOP margin vs Cranswick ~7%, Kerry >12%). Leverage (2.3x) is above sector average but declining.
• Listed peers: Cranswick (CWK), Premier Foods (PFD), Hilton Food Group (HFG); pre-takeout Bakkavor was the closest direct comparable.

Investment thesis

• Well-underwritten multi-year earnings growth from Bakkavor synergies. At least £80m annual pre-tax cost synergies over three years (50% by Jan 2027, 85% by Jan 2028, 100% Jan 2029) on top of underlying 3–5% pro-forma growth, with a fast start already visible in Q3 26 2026-07-22 Q3 trading update.
• Consistent execution and upgrade cadence. Management has twice raised FY26 guidance (from consensus ~£224m to £234–242m); pro-forma AOP growth of 15.3% in H1 26 on only 3.2% revenue growth signals real operational leverage from cost discipline 2026-05-27 Interim Results.
• Optional US divestiture provides deleveraging accelerant. US business held-for-sale (contributed £4m of H1 26 profit; ~£10m FY26 estimate); proceeds would take leverage below 1.5x quickly and could unlock capital return 2026-05-27 Interim Results, Note 12.

Key risks

• Customer concentration. In FY25, five customers each represented >10% of Group revenue (£346m, £321m, £298m, £233m, £199m); relationship quality is high but any renegotiation is materially painful 2025-11-18 FY25 Results, Note 2.
• Integration execution risk and heavy exceptionals. FY26 exceptional items guided at c.£110m plus c.£45m acquisition-related amortisation; £928.8m of customer-relationship intangibles amortising over 15 years compresses reported (not adjusted) earnings materially 2026-05-27 Interim Results, FY26 Guidance.
• Input cost inflation and consumer downtrading. Protein and labour inflation persistent; management notes 75% of raw ingredient spend is on joint models with customers, but timing mismatches historically caused misses (e.g. Q1 26 disappointing profit conversion, subsequently recovered) 2026-01-29 Q1 Trading Update, 2026-05-27 Interim Results.

Operating leverage

Greencore is a moderate operating-leverage business — best captured by the H1 26 read: 3.2% pro-forma revenue growth translated to 15.3% pro-forma AOP growth and +60bps margin, i.e. a ~5x conversion factor. Gross margin is ~32% (H1 26: gross profit £426m on revenue £1,318m) and about 60–65% of the cost base is variable (ingredients, packaging, direct labour), with the remaining ~35–40% (facility overhead, distribution, central costs) delivering the leverage. The £80m synergy programme is the more powerful lever than volume drop-through: at consensus £224m FY26 AOP baseline, each incremental £15m of synergy delivered is a further ~7% to AOP. On a 10–20% revenue beat scenario, operating profit would likely rise ~50–100% (a strong result for the sector, but nothing close to a software-like multiplier) 2026-05-27 Interim Results; 2026-07-22 Q3 Trading Update.

Value-trap signals

None identified. The trajectory is clearly improving: FY25 AOP growth 28.9%, FY26 pro-forma AOP growth guided 17–21%, ROIC 15.0% (FY25), leverage falling, dividend reinstated, buybacks. There is meaningful integration risk but nothing pointing to structural cheapness.

Earnings vs. expectations

• FY25 Q3 (Jul 25): Guided FY25 AOP £118–121m vs prior £114–117m — beat and raise.
• FY25 Trading Update (Oct 25): Guided c.£125m vs consensus £119.5–121.8m — material beat.
• FY25 Full Year (Nov 25): Delivered £125.7m AOP — in line with October upgrade.
• H1 26 (May 26): FY26 guidance reaffirmed at market expectations (~£232m consensus); H1 delivered 15.3% pro-forma AOP growth — in line.
• Q3 26 (Jul 26): Guided FY26 AOP £234–242m for continuing ops vs consensus £224m — beat and raise.

Pattern: a consistent series of beat-and-raise updates over the past 18 months, with management establishing credibility on its guidance-setting.

Conviction: 4 (High)

Anchoring the conviction: (i) clean, well-documented disclosure with detailed APM reconciliations; (ii) consistent recent track record of beat-and-raise; (iii) two independent valuation approaches (EV/EBITDA, P/E) converge on ~260p. Limiting the conviction: (i) large Bakkavor deal only 8 months post-completion — significant integration risk means synergy phasing could slip; (ii) uncertainty on timing and pricing of the US divestiture.